Pathology & Laboratory Medicine

Publications

Filter By Faculty

Filter by Principal Investigator

2019

Cohn CS, Allen ES, Cushing MM, Dunbar NM, Friedman DF, Goel R, et al. Critical developments of 2018: A review of the literature from selected topics in transfusion. A committee report from the AABB's Clinical Transfusion Medicine Committee. Transfusion. 2019;59(8):2733-2748.

Queen D, Hedayat AA, Magro C, Geskin LJ. An unusual cause of bilateral orbital swelling: Immunoglobulin G4-related orbital disease arising in a patient with ulcerative colitis. JAAD Case Rep. 2019;5(7):634-638.

Zadra G, Ribeiro CF, Chetta P, Ho Y, Cacciatore S, Gao X, et al. Inhibition of de novo lipogenesis targets androgen receptor signaling in castration-resistant prostate cancer. Proc Natl Acad Sci U S A. 2019;116(2):631-640.

Canver MC, Satlin MJ, Westblade LF, Kreiswirth BN, Chen L, Robertson A, et al. Activity of Imipenem-Relebactam and Comparator Agents against Genetically Characterized Isolates of Carbapenem-Resistant Enterobacteriaceae. Antimicrob Agents Chemother. 2019;63(9).

Nakanishi Y, Diaz-Meco MT, Moscat J. Serrated Colorectal Cancer: The Road Less Travelled? Trends Cancer. 2019;5(11):742-754.

Cross T, Ransegnola B, Shin J-, Weaver A, Fauntleroy K, VanNieuwenhze MS, et al. Spheroplast-Mediated Carbapenem Tolerance in Gram-Negative Pathogens. Antimicrob Agents Chemother. 2019;63(9).

Shostak E, Ameer R, Gruden J, Jessurun J. A Diagnostic Conundrum: Progressive Tubular Lung Mass in Asymptomatic Young Woman. Chest. 2019;155(5):e131-e135.

Choi S, Wang D, Chen X, Tang LH, Verma A, Chen Z, et al. Function and clinical relevance of RHAMM isoforms in pancreatic tumor progression. Mol Cancer. 2019;18(1):92.

Bhardwaj P, Ikeda T, Zhou XK, Wang H, Zheng XE, Giri DD, et al. Supplemental estrogen and caloric restriction reduce obesity-induced periprostatic white adipose inflammation in mice. Carcinogenesis. 2019;40(7):914-923.

Karass M, Bareja R, Shelkey E, Vlachostergios PJ, Robinson BD, Khani F, et al. Oncogenic Addiction to ERBB2 Signaling Predicts Response to Trastuzumab in Urothelial Cancer. J Natl Compr Canc Netw. 2019;17(3):194-200.